Eli Lilly invests $5.3 billion to increase manufacturing of weight-loss drug Zepbound and diabetes treatment Mounjaro

From NBC Universal: 2024-05-24 15:20:12

Eli Lilly plans to invest $5.3 billion in an Indiana plant to meet high demand for weight-loss drug Zepbound. The company’s total investment at the site will amount to $9 billion, the largest in its history. Manufacturing of Zepbound and diabetes treatment Mounjaro is set to increase by 2028.

Eli Lilly’s manufacturing investment in Indiana aims to boost supplies of Zepbound and Mounjaro, both of which have seen high demand leading to shortages. The new commitment will bring their total investment to $9 billion, the largest in the company’s nearly 150-year history.

The investment by Eli Lilly in its Lebanon site is expected to start making medicines by the end of 2026 and scale up operations through 2028. The plant aims to increase manufacturing capacity for Zepbound and Mounjaro, utilizing the latest technology and automation to enhance efficiency, safety, and quality control.

Eli Lilly plans to increase production of Zepbound, Mounjaro and other incretin drugs with new manufacturing sites in Indiana, North Carolina, Ireland, Germany, and an acquisition in the U.S. The company has spent over $18 billion since 2020 expanding its manufacturing presence.

Investors are optimistic about Eli Lilly’s revenue outlook, prompting the company to raise its full-year revenue forecast by $2 billion. The increased production of Zepbound, Mounjaro and other incretin drugs has boosted confidence among investors regarding Eli Lilly’s performance for the rest of the year.



Read more at NBC Universal: Eli Lilly invests to increase Mounjaro, Zepbound supply